Novo Nordisk: Frenzied rally after the withdrawal of a weight loss drug
Novo Nordisk's stock surged approximately 8% following Hims & Hers's decision to withdraw a low-cost weight loss pill similar to Wegovy amid legal threats from both Novo Nordisk and the FDA.
Novo Nordisk Stock Rises After Cancellation of Copy Pill
Novo Nordisk's stock rose significantly after Hims and Hers announced they would not sell a generic version of Wegovy.
American company gives up the sale of Wegovy copy
The American telehealth company Hims and Hers has decided to cease the sale of a copy of Novo's weight loss medication Wegovy after discussions with industry stakeholders.
Copy of Wegovy pill withdrawn
The company Hims and Hers has ceased offering its cheaper copy of Novo Nordisk's weight loss medication Wegovy after constructive talks with stakeholders.
Novo competitor stops the supply of copy medicine
The company Hims and Hers has decided to stop offering a cheaper copy of Novo Nordisk's weight loss drug Wegovy.
Novo Nordisk calls competitors' copies illegal
Novo Nordisk criticizes Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, claiming it poses significant risks to patient safety and threatens its intellectual property, prompting plans for legal action.
Novo Nordisk strongly criticizes competitor
Novo Nordisk has issued a sharp condemnation of Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, labeling it as illegal mass production that jeopardizes patient safety, and announcing intentions to take legal and regulatory action.
New dive in stocks after competitor's launch
Danish pharmaceutical company Novo Nordisk experiences a sharp drop in stock prices following the launch of a competing weight loss pill by Hims and Hers.
New stock market drop for Novo after copy of new Wegovy pill
Danish pharmaceutical company Novo Nordisk's stock plummeted after the launch of a cheaper version of its Wegovy pill by US firm Hims and Hers.